|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||81.59 - 82.43|
|52 Week Range||66.72 - 92.97|
|PE Ratio (TTM)||11.37|
|Dividend & Yield||3.30 (3.47%)|
|1y Target Est||N/A|
Rating Action: Moody's Affirms A1/VMIG 1 on Green River, WY's LOC-backed VRDBs Series 1994. Global Credit Research- 27 Jul 2017. New York, July 27, 2017-- Moody's Investors Service has affirmed the A1/VMIG ...
Yesterday, shares fop Eli Lilly (LLY) dropped 3% after the pharmaceutical giant beat earnings forecasts but said that a new drug application for a rheumatoid arthritis treatment had been delayed. Leerink ...
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.